^
Association details:
| Biomarker: | SSTR Expression |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | AlphaMedix (ORM-2110) (α radiation emission, SSTR2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I dose-escalation study of AlphaMedix for targeted-alpha-emitter therapy of PRRT-naive neuroendocrine patients.
Published date:
05/19/2021
Excerpt:
This F-I-H clinical study of AlphaMedix shows that PRRT with 212Pb is feasible, well tolerated, and provides substantial reduction in tumor burden to patients with unresectable, metastatic SSTR-expressing NETs.
DOI:
10.1200/JCO.2021.39.15_suppl.4117
Trial ID:
